Roflumilast Foam 0.3% + Vehicle Foam
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Scalp Psoriasis
Conditions
Scalp Psoriasis
Trial Timeline
Aug 24, 2021 → Jun 3, 2022
NCT ID
NCT05028582About Roflumilast Foam 0.3% + Vehicle Foam
Roflumilast Foam 0.3% + Vehicle Foam is a phase 3 stage product being developed by Arcutis Biotherapeutics for Scalp Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT05028582. Target conditions include Scalp Psoriasis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05028582 | Phase 3 | Completed |
| NCT04128007 | Phase 2 | Completed |
| NCT04091646 | Phase 2 | Completed |
Competing Products
7 competing products in Scalp Psoriasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DSXS topical product | Sun Pharmaceutical | Phase 2 | 52 |
| PART 1: Double-blind Placebo-controlled + PART 2: Double-blind Active Treatment Extension | Sun Pharmaceutical | Phase 3 | 77 |
| DSXS + Placebo | Sun Pharmaceutical | Phase 3 | 77 |
| DSXS topical + Vehicle topical | Sun Pharmaceutical | Phase 3 | 77 |
| Betamethasone Scalp Suspension 0.064%;0.0005% + Taclonex® + Placebo topical suspension | Sun Pharmaceutical | Phase 1 | 33 |
| Calcipotriene/Betamethasone Dipropionate + Taclonex® + Placebo | Glenmark Pharmaceuticals | Phase 3 | 77 |
| Secukinumab 300 mg + Placebo | Novartis | Phase 3 | 77 |